findmyKOL
Clinical trialNCT01118052CompletedPhase 2Interventional

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

SponsorGynecologic Oncology GroupEnrollment22Fallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the side effects and how well EGEN-001 works in treating patients with ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that is persistent or has come back. Biological therapies, such as EGEN-001, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama, United States

  • Gynecologic Oncology Group of Arizona

    Phoenix, Arizona, United States

  • University of Colorado Cancer Center - Anschutz Cancer Pavilion

    Aurora, Colorado, United States

  • University of Iowa/holden Comprehensive Cancer Center

    Iowa City, Iowa, United States

  • Sinai Hospital of Baltimore

    Baltimore, Maryland, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, United States

  • Case Western Reserve University

    Cleveland, Ohio, United States

  • Lake University Ireland Cancer Center

    Mentor, Ohio, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, United States

  • Huntsman Cancer Institute/university of Utah

    Salt Lake City, Utah, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Nov 2010
Primary completion
16 Jul 2016
Completion
16 Jul 2016
Last update posted
11 Jan 2018
Registered enrollment
22
Registry id
NCT01118052
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.